For_IN the_DT purposes_NNS of_IN impairment_NN testing_NN of_IN goodwill_NN ,_, goodwill_NN values_NNS have_VBP been_VBN compared_VBN against_IN discounted_VBN forecast_NN cash_NN flows_NNS of_IN the_DT relevant_JJ cash-generating_JJ unit_NN on_IN a_DT value_NN in_IN use_NN basis_NN ._.
The_DT forecasts_NNS include_VBP post_NN tax_NN profit_NN increases_NNS and_CC the_DT corresponding_JJ cash_NN flows_NNS ._.
A_DT discount_NN rate_NN of_IN 10_CD %_NN has_VBZ been_VBN applied_VBN to_TO the_DT calculations_NNS ._.
The_DT carrying_VBG amounts_NNS of_IN goodwill_NN allocated_VBN to_TO cash-generating_JJ units_NNS are_VBP as_IN follows_VBZ :_: 2005 2004 000 000_CD M_NNP &_CC M_NNP product_NN unit_NN 2,511_CD 2,463_CD Alitea_NNP product_NN unit_NN 2,153_CD 2,162_CD 1,869_CD -_: Spirax_NNP Sarco_NNP ,_, Inc._NNP ._.
USA_NNP UK_NNP Supply_NNP product_NN unit_NN 1,625_CD 1,683_CD 1,377_CD 1,384_CD Watson-Marlow_NNP Bredel_NNP ,_, South_NNP Africa_NNP Mitech_NNP product_NN unit_NN 1,175_CD -_: Spirax-Sarco_NNP S._NNP A._NNP S._NNP France_NNP 1,096_CD 1,135_CD Other_JJ cash-generating_JJ units_NNS 3,227_CD 3,035_CD 15,033_CD 11,862_CD 14_CD LOANS_NNP TO_TO SUBSIDIARIES_NNP PARENT_NN COMPANY_NNP 2005 2004 000 000_CD Cost_NN :_: At_IN 1st_CD January_NNP 12,207_CD 11,380_CD Exchange_NNP adjustments_NNS 14_CD 166_CD 12,193_CD 11,546_CD Loans_NNPS 2,678_CD 745_CD Repayments_NNS -_: 84_CD At_IN 31st_CD December_NNP 14,871_CD 12,207_CD Amounts_NNS written_VBN off_RP :_: At_IN 1st_CD January_NNP and_CC 31st_CD December_NNP 1,042_CD 1,042_CD Net_JJ book_NN value_NN :_: At_IN 31st_CD December_NNP 13,829_CD 11,165_CD Spirax-Sarco_NNP Engineering_NNP plc_NN 51_CD
